IMGS-001 is a cytotoxic immune checkpoint inhibitor targeting PD-L1 and PD-L2 and is designed to treat the many “immune-excluded” cancers that are resistant to existing immunotherapies Houston, Texas, Dec. 4, 2025 /PR Newswire/— ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, announced today that the company has been awarded…
Read More
ImmunoGenesis Announces the Formation of Scientific Advisory Board Initial meeting of Scientific Advisory Board (SAB) convened to discuss the first-in-human phase 1a/1b clinical trial of IMGS-001, a dual-specific PD-L1/PD-L2 antibody with cytotoxic killing function designed to treat the many “immune-excluded” cancers that are resistant to existing immunotherapies HOUSTON, July 01,…
Read More
Source: Cancer Focus Fund ImmunoGenesis Expands Phase 1a/b Trial of IMGS-001 for Advanced Solid Tumors to Ochsner MD Anderson Cancer Center First dual-specific PD-L1/PD-L2 antibody with cytotoxic killing function is designed to treat the many “immune-excluded” cancers that are resistant to existing immunotherapies Promising early signals of activity seen as…
Read More
ImmunoGenesis Doses First Patient in Phase 1/2 Clinical Trial of IMGS-101 in Combination With Balstilimab (anti-PD-1) and Zalifrelimab (anti-CTLA-4) in Relapsed or Refractory Advanced Prostate, Pancreatic, and HPV(-) Head & Neck Tumors IMGS-101 is the only known reducer of solid tumor hypoxia, offering the potential to enhance the efficacy of…
Read More
PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy PETACH TIKVA, Israel, Dec. 11, 2024 (GLOBE NEWSWIRE) --PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced a new research and development collaboration with…
Read More
ImmunoGenesis Doses First Patient in Phase 1a/1b Clinical Trial of IMGS-001 in Relapsed or Refractory Advanced Solid Tumors IMGS-001 is the first dual-specific PD-L1/PD-L2 antibody with cytotoxic function designed to treat immune-excluded cancers that are resistant to existing immunotherapies See more here
Read More
ImmunoGenesis and Cancer Focus Fund Announce $4.5 Million Investment to Support First-in-Human Trial of IMGS-001 for Relapsed or Refractory Advanced Solid Tumors First dual-specific PD-L1/PD-L2 antibody with killing function designed to treat the many immune-excluded cancers that are resistant to existing immunotherapies Phase 1b will focus on tumors that are…
Read More
ImmunoGenesis to Present Pre-Clinical Data from Lead Program at Society for Immunotherapy of Cancer Conference See more here
Read More
ImmunoGenesis Appoints Oncology Research Veteran to Lead Immuno-Oncology Clinical Development Targeting Immune-Excluded, “Cold” Cancers Clinical trials for ImmunoGenesis drug candidates to initiate in 2022 See more here
Read More
Data from ImmunoGenesis' Lead Programs Presented in Six Posters at Society for Immunotherapy of Cancer (SITC) Conference See more here
Read More